Nucleic Acid Nanomedicines in Phase II/III Clinical Trials: Translation of Nucleic Acid Therapies for Reprogramming Cells
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
This review presents an integrated analysis of the current-state-of-the-art in nucleic acid nanotherapies and highlights the importance of nanotechnology in the delivery of nucleic acid therapies. While there is no one dominant nanodesign, the diversity of nanodesigns and delivery of different siRNAs, miRNA and DNA to inhibit more than 20 targets in seven disease states in Phase II/III clinical trials reflects the potential of nucleic acid therapies to treat intractable diseases and non-druggable targets. We provide benchmarks to aid in comparing the design, proof-of-concept studies and clinical trials. From this, we demonstrate the importance of generating a strategic framework for integrating clinical 'wish lists' for a means to treat intractable diseases with engineering 'design checklists' for nucleic acid nanotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
Anselmo, A. C., & Mitragotri, S. (2016) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10003 · Cited by 1,321
Liver immunology and its role in inflammation and homeostasis
Robinson, M. W., Harmon, C., & O’Farrelly, C. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2016.3 · Cited by 1,151
Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics
Lorenzer, C., Dirin, M., Winkler, A.-M., Baumann, V., & Winkler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.003 · Cited by 284
Synthesis of IL-6 by Hepatocytes Is a Normal Response to Common Hepatic Stimuli
Norris, C. A., He, M., Kang, L.-I., Ding, M. Q., Radder, J. E., Haynes, M. M., Yang, Y., Paranjpe, S., Bowen, W. C., Orr, A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096053 · Cited by 132
Cited by
Fang, J., Islam, W., & Maeda, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.005 · Cited by 757
Non-viral vectors for RNA delivery
Yan, Y., Liu, X.-Y., Lu, A., Wang, X.-Y., Jiang, L.-X., & Wang, J.-C. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.008 · Cited by 332
Noncoding RNAs in cancer therapy resistance and targeted drug development
Wang, W.-T., Han, C., Sun, Y.-M., Chen, T.-Q., & Chen, Y.-Q. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0748-z · Cited by 265
Nakamura, T., Sato, Y., Yamada, Y., Abd Elwakil, M. M., Kimura, S., Younis, M. A., & Harashima, H. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114417 · Cited by 121
Static DNA Nanostructures For Cancer Theranostics: Recent Progress In Design And Applications
Jahanban-Esfahlan, R., Seidi, K., Jahanban-Esfahlan, A., Jaymand, M., Alizadeh, E., Majdi, H., Najjar, R., Javaheri, T., & Zare, P. (2019) · Nanotechnology, Science and Applications · doi:10.2147/nsa.s227193 · Cited by 50
“(see Table 1).(8) In this section, we will explain the use of static DNs in biomedicine and oncology practice.”
Metadata
- Authors
- Herrera, V. L., Colby, A. H., Ruiz-Opazo, N., Coleman, D. G., & Grinstaff, M. W.
- Venue
- Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2018-08
- Volume
- 13
- Issue
- 16
- Pages
- 2083-2098
- ISSN
- 1743-5889 (ISSN-L)
- 1748-6963
- OpenAlex
- W2890703534
- Cited by
- 44
- References
- 7
- FWCI
- 1.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nucleic Acid Nanomedicines in Phase II/III Clinical Trials: Translation of Nucleic Acid Therapies for Reprogramming Cells. https://app.cochat.ai/papers/10.2217/nnm-2018-0122
- The paper
- Herrera, V. L., Colby, A. H., Ruiz-Opazo, N., Coleman, D. G., & Grinstaff, M. W. (2018). Nucleic Acid Nanomedicines in Phase II/III Clinical Trials: Translation of Nucleic Acid Therapies for Reprogramming Cells. Nanomedicine. https://doi.org/10.2217/nnm-2018-0122
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.